Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-993-5 | CAS number: 90-43-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Genetic toxicity: in vivo
Administrative data
- Endpoint:
- in vivo mammalian cell study: DNA damage and/or repair
- Remarks:
- Type of genotoxicity: DNA damage and/or repair
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2000
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP study according to an generally accepted test procedure
Data source
Referenceopen allclose all
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 000
- Report Date:
- 2000
- Reference Type:
- secondary source
- Title:
- O-Phenylphenol and its Sodium and Potassium Salts: A Toxicological Assessment
- Author:
- Bomhard, E. M. et al.
- Year:
- 2 002
- Bibliographic source:
- Crit. Rev. Toxicol. 32(6):551-626
- Reference Type:
- secondary source
- Title:
- Analysis of Genotoxicity and the Carcinogenic Mode of Action for Ortho-Phenylphenol
- Author:
- Brusick, D.
- Year:
- 2 005
- Bibliographic source:
- Environ Mol Mutagen 45:460-481
Materials and methods
- Principles of method if other than guideline:
- single cell gel/comet assay in rodents for detection of DNA damage, GLP study according to a test procedure scientifically acceptable
- GLP compliance:
- yes
- Type of assay:
- mammalian comet assay
Test material
Reference
- Name:
- Unnamed
- Type:
- Constituent
- Details on test material:
- o-phenylphenol, purity: 99.8%
- Name of test material (as cited in study report): Preventol O extra, OPP, o-Phenylphenol
- Physical state: solid
- Analytical purity: 99.8%
- Purity test date: 29 June 1998, approved until 12 June 2000
- Lot/batch No.: E 0008
- Stability under test conditions: The test item was analysed to be stable in the vehicle at concentrations ranging from 25-200 mg/mL for at least 24 h.
- Storage condition of test material: at room temperature, protected from light
Test animals
- Species:
- mouse
- Strain:
- CD-1
- Sex:
- male
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Charles River Wiga GmbH, Sulzfeld, Germany
- Age at study initiation: 5-8 weeks
- Weight at study initiation: 24-35 g
- Assigned to test groups randomly: [no/yes, under following basis: ]
- Fasting period before study:
- Housing: individually in Makrolon type II cages with bedding of soft wood granules, type S 8/15 (Rettenmaier und Soehne, Fuellstoff-Fabriken, Ellwangen-Holzmuehle, Germany)
- Diet: Altromin 1324 Standard diet (Altromin GmbH, Lage, Germany), ad libitum
- Water: Tap water, ad libitum
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22.5-23
- Humidity (%): 40-62
- Air changes (per hr):
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- - Vehicle(s)/solvent(s) used: olive oil
- Amount of vehicle (if gavage or dermal): 10 mL/kg bw
- Lot/batch no. (if required): 2047001 (Henry Lamotte GmbH) - Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test item and the positive control substance ere suspended in olive oil. For each animal the respective amount of test substance was sepataely suspende in a syringe. - Duration of treatment / exposure:
- 3, 8, and 24 h
- Frequency of treatment:
- single oral dose
- Post exposure period:
- none
Doses / concentrations
- Remarks:
- Doses / Concentrations:
250 and 2000 mg/kg bw
Basis:
actual ingested
- No. of animals per sex per dose:
- 4 males per dose per treatment period
- Control animals:
- yes, concurrent vehicle
- Positive control(s):
- none; no data; ethylmethanesulphonate
- Route of administration: oral (gavage)
- Doses / concentrations: 400 mg/kg bw
- Duration of treatment / exposure: 3 h
Examinations
- Tissues and cell types examined:
- Primary hepatocytes and kidney cells
- Details of tissue and slide preparation:
- CRITERIA FOR DOSE SELECTION:
The dose selection was based on the publication of Sasaki et al. (1997) Mutat Res 395: 189-198
DETAILS OF SLIDE PREPARATION:
- Hepatocytes: After perfusion, incisions were made into each of the liver lobes. Subsequentially, liver cells were carefully collected with the help of a metal comp. The obtained cell suspension was filtered over fine gauze, filled up to 25 mL with cold WEI (Williams Medium E with 1% L-glutamine, 0.1% gentamycin sulfate, without foetal calf serum) and kept on ice for 5-10 min. Afterwards, the resulting supernatant was discarded and the pellet resuspended in 25 mL of cold WEI. Subsequent centrifugation occurred for 3 min at 50 x g and <15°C. Resuspending of the pellet in WEI and second centrifugation were performed as described above. The resulting pelet was resuspended in 5-15 mL WEI. An aliquot was used for the determination of cell viability and cell count by the method of trypan blue exclusion. The obtained viability value of the cell suspension after perfusion is a measure for the substance induced cytotoxicity during in vivo exposure.
- Kidney cells: Both kidneys were cut into half and the cortex region was isolated. The isolated tissue was cut into small pieces with a scalpel, suspended with a pipette and subsequently transferred to 50 mL of a digestion buffer. This buffer containes 25 mL collagenase solution and 25 mL trypsin solution (0.25% trypsin w/v in HBSS. Tissue pieces were incubated under stirring in a waterbath (37°C) for 20 min. After addition of 1 mL foetal calf serum (FCS) the cell suspension was filtered over gross gauze. Bovine serum albumine (10% w/v, 1 mL) was added and the cell suspension centrifuged at 68 x g and 4°C for 5 min. The pellet was resuspended in 25 mL cold HBSS and centrifuged again at 120 x g. The resulting pellet was resuspended in 10 mL cold HBSS: An aliquot was used for the determination of cell viability and cell count by the method of trypan blue exclusion. The obtained viability value of the cell suspension after perfusion is a measure for the substance induced cytotoxicity during in vivo exposure.
METHOD OF ANALYSIS:
The Comet Assay was performed according to the method of Singh et al. (1988) Exp. Cell Res. 175:184-191 with minor modifications. The different steps are comparable to the procedure described by Sasaki et al. (1997) Mutat Res 395: 189-198. Aliquots of the liver and kidney cell suspensions not greater than 100 µL were taken to reach an approximate cell number of 3-5E+04 liver cells and 8-10E+04 kidney cells, respectively. Cells were centrifuged at 180 x g for 6 min. The resulting pellet was mixed with 50 µL of 0.7% low melting agarose (LMA). The cell/LMA suspension was carefully pipetted onto slides already covered with two layers of 0.5% normal melting gaarose (NMA). Afterwards, a second LMA layer (0.7%, 50 µL) was placed on top. After lysis (1 h or overnight) buffer containing NA2EDTA, sacosinate, DMSO and freshly added Triton X-100; without proteinase K), alkaline treatment (20 min, NaOH and Na2EDTA, pH≥13) was performed followed by electrophoresis (60 min, 18 V, 300 mA) and neutralisation (Tris base, pH 7.5). Subsequently, slides were stained with ethidium bromide.
Evaluation of comets was performed using image analysis (Perceptive Instruments, Havehill, UK). Tail length, defined as distance between the middle of the head and the end of the tail, was used as assessment parameter. 50 cells/slide and 2 slides/animal were scored (100 cells total). - Evaluation criteria:
- A response is considered positive, if a chemical induces a dose dependent mean increase of the tail length per dose group of more than 25% above the negative control group. Increases <25% compared to the negative control are considered negative. However, these criteria may be overruled by good scientific judgement.
Results and discussion
Test results
- Sex:
- male
- Genotoxicity:
- negative
- Toxicity:
- yes
- Remarks:
- At 2000 mg/kg bw clinical signs of systemic toxicity was noted. 2/12 animals of that high dose died. No cytotoxicity was noted in hepatocytes and kidney cells of any of the animals of the treatment and control groups (positive and vehicle controls).
- Vehicle controls validity:
- valid
- Negative controls validity:
- not examined
- Positive controls validity:
- valid
Any other information on results incl. tables
Table 1. Table for In Vivo Comet assay results of liver and kidney cells | |||||||||
Organ | Dose group | Tail length [µm, mean* ± SD] | |||||||
3 h | 8 h | 24 h | |||||||
Liver | Neg. control | 34.17 ± 3.24 | 34.58 ± 2.33 | 34.77 ± 1.80 | |||||
OPP |
|
|
| ||||||
250 mg/kg | 40.02 ± 0.84 | 32.63 ± 3.56 | 35.30 ± 4.51 | ||||||
2000 mg/kg | 35.93 ± 3.70 | 31.98 ± 2.14 | 36.80 ± 3.33 | ||||||
EMS400 mg/kg | 48.60 ± 4.58 | 48.72 ± 3.57 | 45.30 ± 1.87 | ||||||
Kidney | Neg. control | 23.23 ± 1.99 | 23.48 ± 0.87 | 20.56 ± 0.45 | |||||
OPP |
|
|
| ||||||
250 mg/kg | 20.93 ± 1.11 | 21.76 ± 1.02 | 21.65 ± 2.57 | ||||||
2000 mg/kg | 19.71 ± 1.00 | 21.54 ± 1.35 | 23.27 ± 3.37 | ||||||
EMS400 mg/kg | 34.60 ± 2.25 | 33.90 ± 2.11 | 32.75 ± 4.05 | ||||||
* 100 cells evaluated | |||||||||
Table 2. Table for Cytogenetic In-Vivo-Test: Cytotoxicity | |||||||||
| negative control | 250 | 2000 | positive control | |||||
Number of cells evaluated | 100 | ||||||||
Cytotoxicity: Liver cells | |||||||||
Sacrifice Time: 3h | Absolute Viabilitya | 79.0±8.04 | 77.6±5.04 | 76.2±5.06 | 74.9±3.16 | ||||
Relative Viabilityb[%] | 100 | 98.1 | 96.4 | 94.8 | |||||
Sacrifice Time: 8h | Absolute Viabilitya | 81.0±5.48 | 77.0±2.27 | 73.5±1.30 | 78.1±4.68 | ||||
Relative Viabilityb[%] | 100 | 95.1 | 90.8 | 96.4 | |||||
Sacrifice Time: 24h | Absolute Viabilitya | 82.9±3.61 | 77.7±4.96 | 74.2±1.72 | 72.3±9.77 | ||||
Relative Viabilityb[%] | 100 | 93.7 | 89.5 | 87.2 | |||||
Cytotoxicity: Kidney cells | |||||||||
Sacrifice Time: 3h | Absolute Viabilitya | 92.3±1.56 | 91.6±2.758 | 86.2±6.37 | 89.9±2.53 | ||||
Relative Viabilityb[%] | 100 | 99.2 | 93.4 | 97.4 | |||||
Sacrifice Time: 8h | Absolute Viabilitya | 92.7±2.86 | 91.3±2.11 | 90.1±2.69 | 93.9±2.31 | ||||
Relative Viabilityb[%] | 100 | 98.5 | 97.2 | 101.3 | |||||
Sacrifice Time: 24h | Absolute Viabilitya | 92.5±1.63 | 92.5±1.73 | 90.0±1.87 | 93.3±2 43 | ||||
Relative Viabilityb[%] | 100 | 100 | 97.3 | 100.9 | |||||
a= mean viability of cell preparation per dose group after perfusion |
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): negative
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

Route: .live1